Objective: This study retrospectively analyzed clinical outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelofibrosis (MF) in a single institution.
Methods: During the past 20 years, 6 patients with MF have undergone allo-HSCT in our institution. We investigated the clinical characteristics and follow-up course of these patients.
Patients: Median age was 47 years (range, 40-52 years). The median interval between diagnosis and allo-HSCT was 12.5 months (range, 5-97 months).
Results: Among these 6 patients, 4 patients were categorized in the high-risk group according to the International Prognostic Scoring System. All 6 patients received myeloablative conditioning regimens, but most of them eventually died of relapse.
Conclusion: In this small series, allo-HSCT resulted in dismal outcomes. Our experience clearly indicates the need for studies with a larger series of patients to evaluate the efficacy of this modality.